Initiate VERSATILE-003 phase 3 trial in HPV16-positive head and neck cancer
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 Feb 2025
- Due
- 30 Sep 2025
- Delivered
- 7 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initiate VERSATILE-003 (V-003)”
What we found
Evidence strength B What the grades mean
PDS Biotech announced initiation of the VERSATILE-003 Phase 3 trial on March 7, 2025, well before the Q3 2025 deadline.
-
B PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Press release announcing trial initiation and open enrollment
-
D PDS Biotech - 2025 News Company newsroom confirms first site initiated, trial open to enrollment
-
D PDS Biotech Reports First Quarter 2025 Financial Results Q1 2025 update reconfirms March 7, 2025 trial initiation and site activation progress
Checked 13 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you PDS Biotechnology Corp? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-PDSB-000213 · Corrections policy